Table 1. Clinical characteristics of patients.
| Characteristics | All | CAB group | LH-RHa monotherapy group | P value |
|---|---|---|---|---|
| Number | 517 | 447 [86] | 70 [14] | |
| Age (years) | 73 [65–78] | 72 [65–78] | 75 [64–79] | 0.443 |
| iPSA (ng/mL) | 285 [63–855] | 294 [62–896] | 229 [71–589] | 0.656 |
| ECOG-PS | ||||
| 0 | 300 [58] | 253 [57] | 47 [67] | 0.047 |
| 1 | 153 [30] | 141 [31] | 12 [17] | |
| ≥2 | 64 [12] | 53 [12] | 11 [16] | |
| Gleason score | ||||
| ≤6 | 5 [1] | 5 [1] | 0 [0] | 0.287 |
| 7 | 51 [10] | 41 [9] | 10 [14] | |
| ≥8 | 461 [89] | 401 [90] | 60 [86] | |
| EOD ≥2 | 290 [56] | 251 [56] | 39 [56] | 0.945 |
| CHAARTED high-volume disease | 327 [63] | 280 [63] | 47 [67] | 0.509 |
| Progression to CRPC | 303 [59] | 265 [59] | 38 [54] | 0.430 |
| Treatment with DTX | 130 [25] | 122 [27] | 8 [11] | 0.004 |
| Treatment with AA and/or ENZ | 113 [22] | 104 [23] | 9 [13] | 0.051 |
| Treatment with estramustine | 122 [24] | 107 [21] | 15 [21] | 0.646 |
| Treatment with BMA | 288 [56] | 258 [58] | 30 [43] | 0.020 |
| follow-up period (months) | 28 [13–52] | 30 [14–54] | 15 [9–31] | <0.001 |
Data are presented as median [IQR] or number [%]. IQR, interquartile range; iPSA, initial prostate-specific antigen; ECOG-PS, Eastern Cooperative Oncology Group performance status; EOD, extent of disease; CRPC, castration resistance prostate cancer; DTX, docetaxel; AA, abiraterone acetate; ENZ, enzalutamide; BMA, bone-modifying agents.